Abraham García Kutzbach

Abraham García Kutzbach

Auto-generated profile, based on publicly available information

Abraham García Kutzbach

Asociación Guatemalteca Anti-Enfermedades Reumáticas (AGAR)

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AGA. García-Kutzbach
A. García-Kutzbach
JCJ. Chacón-Súchite
J. Chacón-Súchite
HGH. García-Ferrer
H. García-Ferrer
III. Iraheta
I. Iraheta

1 June 2012 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
AOAriel Obregón-Ponce
Ariel Obregón-Ponce
IIIsa Iraheta
Isa Iraheta
HGHelga García-Ferrer
Helga García-Ferrer
BMBayardo Mejia
Bayardo Mejia
AGAbraham García-Kutzbach
Abraham García-Kutzbach
Background Guatemala is a multiethnic, multilingual, and multicultural country. We have evaluated 2 different ethnic groups from (1) San Juan Sacatepéquez County (SJSC), a rural population (30% illiterate), with 65% from Kaqchiquel ethnic group; and (2) Zone 5 of Guatemala City (Z5GC), an urban population (6.6% illiterate), with 95.5% mestizos. Objective This study aimed to measure simultaneously the prevalence of rheumatic diseases in these 2 Guatemalan populations, both located in the State of Guatemala. Methods A convenience sample of 4000 inhabitants 15 years and older was selected in each group. The Core Community Oriented Program for Control of Rheumatic Diseases Questionnaire was used in this survey. Phase 1 was for screening (identification of study subjects), phase 2 was for obtaining information from subjects with musculoskeletal complaints, and phase 3 was for rheumatologic diagnostic purposes. Phases 1 and 2 were performed by 6 interviewers. Phase 3 was completed by 4 rheumatologists. Results In phase I, 8000 subjects were identified in both groups. In phase II, 949 subjects reported musculoskeletal complaints: 371 (39%) in Z5GC and 578 (61%) in SJSC. In phase III, 419 patients were clinically evaluated: 141 (34%) in Z5GC and 278 (66%) in SJSC. The most prevalent musculoskeletal diseases were (1) osteoarthritis, (2) soft tissue rheumatism, (3) rheumatoid arthritis, (4) low back pain, and (5) arthralgias of unknown etiology. Osteoarthritis and soft tissue rheumatism were significantly more common in the rural population. Conclusions The most prevalent musculoskeletal diseases in Guatemala seem to be similar to those in most previous Community Oriented Program for Control of Rheumatic Diseases studies. Most subjects were still working. Further studies examining medical care received and impact on function can now be of interest.

25 April 2016 in Rheumatology
Verified
Journal Article
Open access
PDF file
NVNathan Vastesaeger
Nathan Vastesaeger
AKAbraham Garcia Kutzbach
Abraham Garcia Kutzbach
HAHoward AMITAL
Howard AMITAL
Karel PavelkaKarel Pavelka
Karel Pavelka
MLMaría Alicia Lazaro
María Alicia Lazaro
PDPatrick Durez
Patrick Durez
Objective. To create a tool to predict probability of remission and low disease activity (LDA) in patients with RA being considered for anti-TNF treatment in clinical practice. Methods. We analysed data from GO-MORE, an open-label, multinational, prospective study in biologic-naïve patients with active RA (DAS28-ESR ⩾3.2) despite DMARD therapy. Patients received 50 mg s.c. golimumab (GLM) once monthly for 6 months. In secondary analyses, regression models were used to determine the best set of baseline factors to predict remission (DAS28-ESR <2.6) at month 6 and LDA (DAS28-ESR ⩽3.2) at month 1. Results. In 3280 efficacy-evaluable patients, of 12 factors included in initial regression models predicting remission or LDA, six were retained in final multivariable models. Greater likelihood of LDA and remission was associated with being male; younger age; lower HAQ, ESR (or CRP) and tender joint count (or swollen joint count) scores; and absence of comorbidities. In models predicting 1-, 3- and 6-month LDA or remission, area under the receiver operating curve was 0.648–0.809 (R2 = 0.0397–0.1078). The models also predicted 6-month HAQ and EuroQoL-5-dimension scores. A series of matrices were developed to easily show predicted rates of remission and LDA. Conclusion. A matrix tool was developed to show predicted GLM treatment outcomes in patients with RA, based on a combination of six baseline characteristics. The tool could help provide practical guidance in selection of candidates for anti-TNF therapy.

20 November 2023 in Revista de la Facultad de Medicina
Verified
Journal Article
Open access
PDF file
EMEmmanuel Guevara Mejia
Emmanuel Guevara Mejia
AOAndrea Bran Ordoñez
Andrea Bran Ordoñez
YBYoell David Bautista
Yoell David Bautista
AKAbraham García Kutzbach
Abraham García Kutzbach
Introducción: Crain, en 1961, identificó presencia de inflamación en pacientes con osteoartritis de mano utilizando para ello el término de osteoartritis inflamatoria, cinco años después Peter et al. Observó alteraciones radiográficas erosivas en algunos casos de osteoartritis de mano. Objetivos: identificar la prevalencia de Osteoartritis erosiva de mano (EHOA), sus factores de riesgo y la sensibilidad de los criterios propuestos por Anandarajah. Metodología: Descriptivo de corte transversal, se comparó 400 pacientes 22 EHOA Y 378 Osteoartritis de manos (HOA) de enero 2021 a febrero 2022 recolectada por revisión de expedientes, los criterios de Anandarajah fueron utilizados. Resultados: La prevalencia de EHOA es de 5.82% por sexo varía del 4.76 al 1.06% en mujeres y hombres respectivamente, su inicio fue abrupto, el principal factor de riesgo es obesidad con diferencia estadísticamente significativa entre los grupos estudiados, otros factores son sexo femenino, hipertensión, dislipidemia, diabetes mellitus, trabajo manual y trauma articular con valores individuales mas elevados comparados con la HOA. Los criterios diagnósticos estudiados muestran una sensibilidad del 65% Conclusiones: EHOA presentó mayor componente inflamatorio, inicio abrupto de los síntomas y asociación a factores de riesgo que le predisponen a un estado proinflamatorio crónico; consideramos que la EHOA podría tener una etiopatogenia distinta que la diferencia de la HOA, empero estudios histológicos grandes serian necesarios. Palabras clave: Osteoartritis, Osteoartritis de mano, Osteoartritis de mano erosiva, incapacidad funcional, obesidad, dolor, erosiones centrales.  

5 May 2023 in Global Rheumatology
Verified
Journal Article
Open access
AOAndrea Bran Ordóñez
Andrea Bran Ordóñez
JMJuan Emmanuel Guevara Mejía
Juan Emmanuel Guevara Mejía
YEYoell David Bautista Esquivel
Yoell David Bautista Esquivel
AKAbraham García Kutzbach
Abraham García Kutzbach
Primera descripción de casos de esta enfermedad en la región que servirá para futuras referencias. Patología autoinmune infrecuente e infra diagnosticada. Mayoría presentó todos los criterios mayores de Yamaguchi, lo que facilitó el diagnóstico. La ferritina es un marcador de inflamación y no todos la normalizaron luego de recibir tratamiento; también es apoyo para optimización de esteroides. La mayoría se adhirió bien al tratamiento y seguimiento.

21 June 2021 in Global Rheumatology
Verified
Journal Article
Closed access
ALAlex López
Alex López
MBMarvin Bustamante
Marvin Bustamante
LKLuis Kramer
Luis Kramer
JAJuan Pablo Araica
Juan Pablo Araica
YMYeny Maldonado
Yeny Maldonado
AKAbraham García Kutzbach
Abraham García Kutzbach
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by the production of autoantibodies generating systemic inflammation and multiorgan involvement. In this study we describe the classificatory criteria, activity index, organ damage index and treatment of patients treated at the headquarters of the Guatemalan Association Against Rheumatic Diseases (AGAR) located in Guatemala City